News summary

CureGene Presents Two Preclinical Studies of CG-0416 at Obesity Week 2026

Source: PR Newswire • Published: 16 Nov 2026, 04:15

Summarized by Masters of Longevity from PR Newswire.

CureGene reported preclinical mouse data showing large weight loss with combination therapy.

CureGene Presents Two Preclinical Studies of CG-0416 at Obesity Week 2026
Key Takeaways
  • Combination therapy was reported to produce 35.2% weight loss.
  • CG-0416 monotherapy was reported to spare muscle in DIO mice.
  • Findings are preclinical and do not establish human efficacy.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.